



September 2008

Approval of Buprenorphine ETHYPHARM by the United Kingdom Health Authority

Ethypharm announce that they have just obtained the marketing authorization of its Buprenorphine for its partner Arrow Generics.

This concerns a range of modified release tablets of 3 dosage strengths : 0.4 mg, 2 mg, & 8 mg.

The MA was granted in the United Kingdom on 6 May last. Its registration via the decentralized procedure was initiated on 1 March 2007 by Arrow Generics, and finalized on 11 March 2008.

This new marketing authorization brings with it the prospect of a notable augmentation in the market shares of Buprenorphine, as well as a strong competitive position of this product on the European Market.

In 2006 a Licensing Agreement was concluded with the Arrow Laboratory, Ethypharm's first Partner to launch the Subutex® generic in France.

In April 2007, the product was also marketed on the French territory by the Merck Generiques Laboratory. Registered in Europe, the product was licensed in July 2007 by Nycomed in Scandinavia : Denmark then Norway and Sweden.

Arrow, already Ethypharm's Partner for Buprenorphine in France, plan to launch the product in the United Kingdom next September.

Ethypharm
194 Bureaux de la Colline
92 213 Saint-Cloud, France

Tel: +33 1 41 12 17 20
www.ethypharm.com